These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 7919566)

  • 1. Tacrine: first drug approved for Alzheimer's disease.
    Crismon ML
    Ann Pharmacother; 1994 Jun; 28(6):744-51. PubMed ID: 7919566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease: how to give and monitor tacrine therapy.
    Woo JK; Lantz MS
    Geriatrics; 1995 May; 50(5):50-3. PubMed ID: 7737527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maximizing function in Alzheimer's disease: what role for tacrine?
    Smucker WD
    Am Fam Physician; 1996 Aug; 54(2):645-52. PubMed ID: 8701842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease.
    Wagstaff AJ; McTavish D
    Drugs Aging; 1994 Jun; 4(6):510-40. PubMed ID: 7521234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Velnacrine for Alzheimer's disease.
    Birks J; Wilcock GG
    Cochrane Database Syst Rev; 2004; (2):CD004748. PubMed ID: 15106259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WITHDRAWN: Tacrine for Alzheimer's disease.
    Qizilbash N; Birks J; Lopez Arrieta J; Lewington S; Szeto S
    Cochrane Database Syst Rev; 2007 Jul; (3):CD000202. PubMed ID: 17636619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease.
    Watkins PB; Zimmerman HJ; Knapp MJ; Gracon SI; Lewis KW
    JAMA; 1994 Apr; 271(13):992-8. PubMed ID: 8139084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrine for Alzheimer's disease.
    Qizilbash N; Birks J; López-Arrieta J; Lewington S; Szeto S
    Cochrane Database Syst Rev; 2000; 1999(2):CD000202. PubMed ID: 10796507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.
    Farlow M; Gracon SI; Hershey LA; Lewis KW; Sadowsky CH; Dolan-Ureno J
    JAMA; 1992 Nov; 268(18):2523-9. PubMed ID: 1404819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
    Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
    N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.
    Knapp MJ; Knopman DS; Solomon PR; Pendlebury WW; Davis CS; Gracon SI
    JAMA; 1994 Apr; 271(13):985-91. PubMed ID: 8139083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donepezil use in Alzheimer disease.
    Barner EL; Gray SL
    Ann Pharmacother; 1998 Jan; 32(1):70-7. PubMed ID: 9475825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methodology, results and quality of clinical trials of tacrine in the treatment of Alzheimer's disease: a systematic review of the literature.
    Arrieta JL; Artalejo FR
    Age Ageing; 1998 Mar; 27(2):161-79. PubMed ID: 16296676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.
    Chatellier G; Lacomblez L
    BMJ; 1990 Feb; 300(6723):495-9. PubMed ID: 2107926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tacrine therapy for the dementia of Alzheimer's disease.
    Manning FC
    Am Fam Physician; 1994 Sep; 50(4):819-26. PubMed ID: 8079912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steady-state pharmacokinetics of tacrine in patients with Alzheimer's disease.
    Cutler NR; Sedman AJ; Prior P; Underwood BA; Selen A; Balogh L; Kinkel AW; Gracon SI; Gamzu ER
    Psychopharmacol Bull; 1990; 26(2):231-4. PubMed ID: 2236461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrine for Alzheimer's disease.
    Qizilbash N; Birks J; Lopez Arrieta J; Lewington S; Szeto S
    Cochrane Database Syst Rev; 2000; (3):CD000202. PubMed ID: 10908463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A risk-benefit assessment of tacrine in the treatment of Alzheimer's disease.
    Samuels SC; Davis KL
    Drug Saf; 1997 Jan; 16(1):66-77. PubMed ID: 9010644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease.
    Allain H; Schück S; Lebreton S; Strenge-Hesse A; Braun W; Gandon JM; Brissot P
    Dement Geriatr Cogn Disord; 1999; 10(3):181-5. PubMed ID: 10325444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrine in Alzheimer's disease: pharmacokinetic and clinical comparison of oral and rectal administration.
    Ahlin A; Hassan M; Junthé T; Nybäck H
    Int Clin Psychopharmacol; 1994; 9(4):263-70. PubMed ID: 7868848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.